Details

Autor(en) / Beteiligte

• Mukhopadhyay, Asima

Titel

EP365/#1142 Implementation of novel, alternative and affordable options for ovarian cancer care throughout the entire journey: a KolGo Trg approach

Ist Teil von

• International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A202-A202

Ort / Verlag

Oxford: BMJ Publishing Group Ltd

Erscheinungsjahr

2022

Beschreibungen/Notizen

• ObjectivesWith a predicted 50% rise in incidence and mortality from ovarian cancer by 2040, health-inequality and access to recent paradigm changing treatment options in ovarian cancer care remain a significant challenge in low resource settings. Kolkata Gynecological Oncology Trials and Translational Research Group (KolGo Trg), the first GCIG group from India was formed in 2018 with a mission to address this cancer care gap through academic clinical studies/education/training.MethodsA road map was developed for implementation of a series of sequential studies (OCRN): Optimal surgery/training, targeted/precision surgery in frontline setting ( HIPEC-HR), low- cost predictive biomarkers (academic HRD test- HRDAIC), Nurse-led genetic counselling/awareness ( NUGENA), low-cost treatment options for biochemical recurrence (HOTROC), affordable approaches to parpi therapy ( IPIROC), parpi in arsenic endemic zones (BIODIVARSITY), QOL-studies ( SOCQER-IND), health-economics and willingness to pay studies (HEPTROC), Translational studies (PROVAT), Health policy studies (ROCK- regional ovarian cancer centre, Kolkata), novel statistical designs ( SMART- PARP and RCT- rationalising and reducing the cost of running randomised controlled trials in low resource settings), survivorship/patient-public-involvement ( KOLGO-SURV/SARBOJAYA).ResultsWe have successfully initiated and implemented all these studies; barriers and challenges are being measured through the REAIM framework for implementation research i.e., feasibility, accessibility, acceptability, cost effectiveness, scalability (table 1. www.kolgotrg.org). Some of our studies are being considered for wider global participation through GCIG.Abstract EP365/#1142 Figure 1Abstract EP365/#1142 Table 1ConclusionsThis systematic model for addressing novel and affordable indigenous solutions for each step of cancer care could be an exemplar for other cancer types in LMICs.